British drugmaker GSK has struck a deal to allow low-cost generic versions of its long-acting HIV preventive medicine to be used in the developing world, including sub-Saharan Africa where the virus remains a leading cause of death.
https://www.pharmalive.com/wp-content/uploads/2021/12/ApretudeVial.jpg10301030Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-07-28 10:08:542022-07-28 11:37:05Cheap copies of GSK’s HIV prevention drug could be ready in 2026